openPR Logo
Press release

Antiplatelet Drugs Medication: A Review of Pharmacology and Management in the Perioperative Period | Eminent Players Sanofi, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH, Daiichi Sankyo, Inc.

03-23-2019 06:17 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Global Antiplatelet Drugs Market

Global Antiplatelet Drugs Market

Antiplatelet drugs are prescribed to individuals with a history of heart attacks and these drugs aid in reducing reoccurrence of heart attacks. Some of the antiplatelet medications include, aspirin, clopidogrel, prasugrel, and ticagrelor. Aspirin is recommended for all patients with Acute Coronary Syndrome (ACS), in the absence of hypersensitivity. It is prescribed along with one of the oral antiplatelet agents including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed for patients suffering from ACS and for those undergoing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor aid in preventing atherothrombotic events in adult patients with ACS, and those who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.

Get Access on Research Analysis and Growth Strategy: https://www.coherentmarketinsights.com/insight/request-pdf/2190

Antiplatelet Drugs Market - Competitive Landscape

Key players operating in the global antiplatelet drugs market include, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company. Manufactures in the antiplatelet drugs market are focused on targeting either surface receptors or enzymes in the platelet in order to protect against unwanted clot formation following initial platelet activation.

The global antiplatelet drugs market size was valued at US$ 1.5 billion in 2017 and is expected to witness a CAGR of 7.6% over the forecast period (2018 – 2026).

Increasing incidence of cardiovascular diseases is expected to drive growth of the antiplatelet drugs market

Increasing prevalence of cardiovascular disorders, growing geriatric population, and sedentary lifestyle are some of the major factors driving the global antiplatelet drugs market growth. Cardiovascular diseases are the principal cause of death in the developed and emerging economies. According to a report by Centers for Disease Control and Prevention (CDC), 2015, around 800,000 people in the U.S. die annually due to stroke and other cardiovascular diseases. Some of the common cardiovascular diseases include, rheumatic heart disease, hypertensive heart disease, inflammatory heart disease, ischemic heart disease, and cerebrovascular heart disease.

Antiplatelet Drugs Market - Regional Insights

On the basis of region, the global antiplatelet drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe antiplatelet drugs market are expected to foresee significant growth by 2026 as cardiovascular diseases are the principal cause of death in these regions. According to a European Heart Journal 2014 study, Coronary Heart Diseases (CHD), particularly Myocardial Infarction (MI), is responsible for around 1.8 million deaths in Europe, annually.

Detailed Segmentation:

Global Antiplatelet Drugs Market, By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors

Global Antiplatelet Drugs Market, By Mode of Administration:
- Oral
- Intravenous

Global Antiplatelet Drugs Market, By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others

If you have any speacial requirment, Talk to our Analyst @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2190

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antiplatelet Drugs Medication: A Review of Pharmacology and Management in the Perioperative Period | Eminent Players Sanofi, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH, Daiichi Sankyo, Inc. here

News-ID: 1668214 • Views:

More Releases from Coherent Market Insights

Magnesium Oxide Market Size 2024: New Opportunities, Geographical Analysis, and Forecast Until 2031 | Martin Marietta Materials Inc., Grecian Magnesite S.A., Premier Magnesia
Magnesium Oxide Market Size 2024: New Opportunities, Geographical Analysis, and …
The latest report published by Coherent Market Insights highlights the growth prospects of the Magnesium Oxide Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such
Colostrum Market Key Growth Drivers, Latest Opportunities, Increasing Demand, and Forecast By 2024-2031 | APS Biogroup, Biostrum Nutritech Pvt. Ltd.
Colostrum Market Key Growth Drivers, Latest Opportunities, Increasing Demand, an …
The latest report published by Coherent Market Insights highlights the growth prospects of the Colostrum Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such as
Steam Turbine Market Size 2024: Industrial Insights including Manufacturing Details and Forecast Till 2031 | General Electric (GE), Siemens Energy
Steam Turbine Market Size 2024: Industrial Insights including Manufacturing Deta …
The latest report published by Coherent Market Insights highlights the growth prospects of the Steam Turbine Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such
Protein Supplements Market Share: Size, Growth, Key Vendors, Trends, and Forecast From 2024-2031 | Mondelez Company, Meiji Holdings Co Ltd.
Protein Supplements Market Share: Size, Growth, Key Vendors, Trends, and Forecas …
The latest report published by Coherent Market Insights highlights the growth prospects of the Protein Supplements Market from 2024 to 2031. In-depth research on Industry Size, Share, Business Analysis, Growth Factors, and Regional Forecast. The market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The market study includes information on market factors such

All 5 Releases


More Releases for Antiplatelet

The Antiplatelet Drugs Market To Thrive Backed By Wearable Technology
Antiplatelet drugs are incorrectly referred to as blood thinners. They do not thin the blood, but interfere with the vital process by which the blood clots. Antiplatelet drugs usually reduce the aggregation of blood cells, reducing potentially harmful clots. Giving antiplatelet drugs to people at high risk of heart disease can help avoid the risk of stroke and heart attack . Get Sample Copy of This Report @
Antiplatelet Drugs Market - Increasing incidence of cardiovascular diseases is e …
The report presents an in-depth assessment of the Antiplatelet Drugs Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles, and strategies. The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of
Dual Antiplatelet Therapy Market Value Insights, Analysis and Segments 2018 to 2 …
Dual antiplatelet therapy is defined as the use of aspirin and P2Y12 receptor inhibitor to prevent blood clotting, and through a double mechanism, it prevents thrombotic complications. The dual antiplatelet therapy is often prescribed for patients who had a cardiac attack, had coronary artery bypass graft surgery (CABG), or were treated with stents in coronary arteries. Growing prevalence of cardiovascular disease on the coattails of changing lifestyles habits is expected
Dual Antiplatelet Therapy Market: Latest Report with Forecast 2018 to 2028
Platelets are small blood particles that clump together to form clots. Sometimes, these clots may lead to myocardial infarction or a sudden blockage in the coronary artery. Antiplatelets are a class of drugs that inhibit blood clot formation. Many heart attack and stroke patients are treated with two types of antiplatelet drugs to prevent blood clotting. This is known as dual antiplatelet therapy. Dual antiplatelet therapy is a combination therapy
Antiplatelet Drugs Market Registering a Strong Growth by 2025
Antiplatelet drugs are wrongly referred to as the blood thinning drugs. They don’t thin the blood but instead interfere with the important process by which blood clots. Antiplatelet agent normally decrease the clumping of blood cells thereby decreasing the potentially harmful blood clots. People who are at high risk of heart disease when given antiplatelet agents, their risks of strokes and heart attacks can be avoided. Antiplatelet agents are widely used
Antiplatelet Drugs Market Significantly Expand During 2017 - 2025
Antiplatelet drugs are wrongly referred to as the blood thinning drugs. They don’t thin the blood but instead interfere with the important process by which blood clots. Antiplatelet agent normally decrease the clumping of blood cells thereby decreasing the potentially harmful blood clots. People who are at high risk of heart disease when given antiplatelet agents, their risks of strokes and heart attacks can be avoided. Antiplatelet agents are widely used